Article
Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.
Biochemistry - 7 Feb 2006
Tong Xiao, Guo Zhuyan, Wright-Minogue Jacquelyn, Xia Ellen, Prongay Andrew, Madison Vincent, Qiu Ping, Venkatraman Srikanth, Velazquez Francisco, Njoroge F George, Malcolm Bruce A
Abstract excerpt
HCV drug discovery efforts have largely focused on genotype 1 virus due to its prevalence and relatively poor response to current therapy. However, patients infected with genotype 2 and 3 viruses account for a significant number of cases and would also benefit from new therapies. In vitro studies using two chemically distinct protease inhibitors with clinical potential showed that one, VX-950, was equally active...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.